Drugs / Zebutinib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05992597 | Aug 2022 → Aug 2025 overdue | mantle cell lymphoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04980859 | Sep 2021 → Sep 2025 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zebutinib | “ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.” NCT05992597 ↗ |
| Route | Oral | “Zebutinib 160 mg bid oral treatment” NCT04980859 ↗ |